Jennifer Evers Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 116 Jared St, Waynesville, MO 65583 Phone: 503-740-4949 |
Mrs. Melissa Christie Petty, OTR/L Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 320 Ichord Ave, Suite F, Waynesville, MO 65583 Phone: 573-881-1418 Fax: 573-774-2487 |
Ma Sanchez, OT Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 700 Birch Ln, Waynesville, MO 65583 Phone: 573-774-6456 Fax: 573-774-6778 |
News Archive
APP Pharmaceuticals, Inc., a wholly owned subsidiary of Fresenius Kabi Pharmaceuticals Holding, Inc., (NASDAQ: APCVZ) announced today that it has received approval from the U.S. Food and Drug Administration (FDA) to market Sumatriptan Succinate Injection, USP, in two dosage strengths.
Synta Pharmaceuticals Corp., a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today reported financial results and operational highlights for the quarter ended September 30, 2010.
The emerging idea that obesity may have an infectious origin gets new support in a cross-sectional study by University of California, San Diego School of Medicine researchers who found that children exposed to a particular strain of adenovirus were significantly more likely to be obese.
The PATH Malaria Vaccine Initiative (MVI) announced today that it has entered into a collaboration with Dutch biopharmaceutical company Crucell N.V. and GlaxoSmithKline (GSK). This collaboration is aimed at developing a second-generation vaccine against malaria—a deadly disease that kills close to 800,000 people annually, most of them young children under age five in Africa. MVI drives the development of malaria vaccines by joining its scientific, managerial, and field expertise with companies, universities, and governments to test potential malaria vaccines and invest in those with the most promise.
Thermo Fisher Scientific Inc., the world leader in serving science, and PREMIER Biosoft, have announced an agreement to co-market PREMIER Biosoft's SimGlycan® software. The agreement aims to advance glycobiology by dramatically speeding the characterization of complex glycans through automated interpretation of the rich data produced by Thermo Scientific mass spectrometer systems.
› Verified 5 days ago